Department of Cardiology, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, French Alliance for Cardiovascular Trials, INSERM U1148, Laboratory for Vascular Translational Science, 46 rue Henri Huchard, 75018 Paris, France.
Université Paris Cité, 85 boulevard Saint-Germain, 75006 Paris, France.
Eur Heart J. 2024 Feb 1;45(5):366-375. doi: 10.1093/eurheartj/ehad556.
Data on new-onset atrial fibrillation (NOAF) in patients with chronic coronary syndromes (CCS) are scarce. This study aims to describe the incidence, predictors, and impact on cardiovascular (CV) outcomes of NOAF in CCS patients.
Data from the international (45 countries) CLARIFY registry (prospeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease) were used. Among 29 001 CCS outpatients without previously reported AF at baseline, patients with at least one episode of AF/flutter diagnosed during 5-year follow-up were compared with patients in sinus rhythm throughout the study.
The incidence rate of NOAF was 1.12 [95% confidence interval (CI) 1.06-1.18] per 100 patient-years (cumulative incidence at 5 years: 5.0%). Independent predictors of NOAF were increasing age, increasing body mass index, low estimated glomerular filtration rate, Caucasian ethnicity, alcohol intake, and low left ventricular ejection fraction, while high triglycerides were associated with lower incidence. New-onset atrial fibrillation was associated with a substantial increase in the risk of adverse outcomes, with adjusted hazard ratios of 2.01 (95% CI 1.61-2.52) for the composite of CV death, non-fatal myocardial infarction, or non-fatal stroke, 2.61 (95% CI 2.04-3.34) for CV death, 1.64 (95% CI 1.07-2.50) for non-fatal myocardial infarction, 2.27 (95% CI 1.85-2.78) for all-cause death, 8.44 (95% CI 7.05-10.10) for hospitalization for heart failure, and 4.46 (95% CI 2.85-6.99) for major bleeding.
Among CCS patients, NOAF is common and is strongly associated with worse outcomes. Whether more intensive preventive measures and more systematic screening for AF would improve prognosis in this population deserves further investigation.
关于慢性冠状动脉综合征(CCS)患者中新发心房颤动(NOAF)的数据很少。本研究旨在描述 CCS 患者中 NOAF 的发生率、预测因素及其对心血管(CV)结局的影响。
使用国际(45 个国家)CLARIFY 登记处(前瞻性观察性研究稳定型冠状动脉疾病患者的纵向登记)的数据。在 29001 例基线时无先前报告的 AF 的 CCS 门诊患者中,与整个研究期间窦性心律的患者相比,比较了在 5 年随访期间至少有一次 AF/房扑发作的患者。
NOAF 的发生率为 1.12[95%置信区间(CI)1.06-1.18]每 100 患者年(5 年累积发生率:5.0%)。NOAF 的独立预测因素是年龄增长、体重指数增加、估计肾小球滤过率低、白种人、饮酒和左心室射血分数低,而高甘油三酯与较低的发生率相关。新发心房颤动与不良结局风险显著增加相关,复合心血管死亡、非致死性心肌梗死或非致死性卒中的调整后危险比为 2.01(95%CI 1.61-2.52),心血管死亡的危险比为 2.61(95%CI 2.04-3.34),非致死性心肌梗死的危险比为 1.64(95%CI 1.07-2.50),全因死亡的危险比为 2.27(95%CI 1.85-2.78),心力衰竭住院的危险比为 8.44(95%CI 7.05-10.10),大出血的危险比为 4.46(95%CI 2.85-6.99)。
在 CCS 患者中,NOAF 很常见,与预后更差密切相关。在这一人群中,是否需要更强化的预防措施和更系统的 AF 筛查来改善预后,值得进一步研究。